| Literature DB >> 35281745 |
Yuli Cheng1, Yan Yu1, Qinghui Zhuang1, Lei Wang2, Bin Zhan3, Suqin Du1, Yiqi Liu1, Jingjing Huang1, Junfeng Hao4, Xinping Zhu1.
Abstract
Helminths and helminth-derived products hold promise for treating joint bone erosion in rheumatoid arthritis (RA). However, the mechanisms of helminths ameliorating the osteoclastic bone destruction are incompletely understood. Here, we report that Trichinella spiralis infection or treatment with the excreted/secreted products of T. spiralis muscle larvae (MES) attenuated bone erosion and osteoclastogenesis in mice with collage-induced arthritis (CIA) through inhibiting M1 monocyte/macrophage polarization and the production of M1-related proinflammatory cytokines. In vitro, MES inhibited LPS-induced M1 macrophage activation while promoting IL-4-induced M2 macrophage polarization. Same effects of MES were also observed in monocytes derived from RA patients, wherein MES treatment suppressed LPS-induced M1 cytokine production. Moreover, MES treatment attenuated LPS and RANKL co-stimulated osteoclast differentiation from the RAW264.7 macrophages through inhibiting activation of the NF-κB rather than MAPK pathway. This study provides insight into the M1 subset as a potential target for helminths to alleviate osteoclastic bone destruction in RA.Entities:
Keywords: Biological sciences; Immunology; Orthopedics
Year: 2022 PMID: 35281745 PMCID: PMC8914552 DOI: 10.1016/j.isci.2022.103979
Source DB: PubMed Journal: iScience ISSN: 2589-0042
Figure 1Trichinella spiralis infection alleviates bone erosion and inhibits osteoclastogenesis in the joints of mice with collagen-induced arthritis (CIA)
(A) Representative 3D images of the hind paws from mice of control, CIA or T. spiralis (Ts) infected CIA groups (left panel). Significant bone erosion and disruption was pointed by red arrows. The bone volume/total volume ratio (BV/TV) and trabecular thickness (Tb.Th) were quantified in the different groups of mice (right panel).
(B) Joint synovium sections were stained with TRAP (left panel, scale bar, 200 μm) and the numbers of osteoclasts (OCs) (red arrows) per view field were counted using ImageJ software (right panel).
(C) Peripheral blood mononuclear cells (PBMCs) from the different groups of mice were stimulated with murine RANKL (50 ng/mL) and M-CSF (30 ng/mL) for 7 days and then stained with TRAP. The numbers of TRAP-stained multinucleated OCs (≥3 nuclei, pointed by red arrows) (left panel, scale bar, 500 μm and 200 μm) were counted per field of view (right panel).
(D) Total RNA was extracted from M-CSF- and RANKL-stimulated monocytes isolated from PBMCs and the relative gene expression levels of TRAP, NFAT, MMP-9, c-Fos, and cathepsin K were measured by RT-qPCR. Data are expressed as the means ± SEM from three independent experiments (n = 5 mice per group). ∗p <0.05; ∗∗p <0.01.
Figure 2Trichinella spiralis infection inhibits M1 macrophage polarization in mice with collagen-induced arthritis (CIA)
(A) Flow cytometry gating strategy to define CD11b+CD115+ monocytes among peripheral blood mononuclear cells (PBMCs) and representative dot plots showing the M1 (NOS2+) and M2 (CD206+) from mice of control, CIA and T. spiralis (Ts) infected CIA group.
(B) The percentage of M1 and M2 monocytes and the M1/M2 ratio in each group.
(C) Flow cytometry gating strategy to define CD11b+F4/80+ peritoneal macrophages and representative dot plots showing the M1 (NOS2+) and M2 (CD206+) from mice of each group.
(D) The percentages of M1 (NOS2+) and M2 (CD206+) macrophages and the M1/M2 ration in each group.
(E) Representative photomicrographs of multiplex immunofluorescence staining for M1 (NOS2+, green) and M2 (CD206+, white) in synovial macrophages (F4/80+, red) on day 49 after the first immunization with type Ⅱ collagen (CⅡ). Nuclei were counterstained with DAPI (blue).
(F) The percentage of M1 and M2 macrophages and the M1/M2 ratio in the synovium of joints in each group.
(G) Spearman’s correlation analysis for the numbers of osteoclasts (OCs) differentiated from blood monocytes and the proportion of M1 population in PBMCs from CIA mice with or without T. spiralis infection.
(H) Spearman’s correlation analysis for the numbers of OCs in joint synovium sections and synovial macrophages of CIA mice with or without T. spiralis infection. Data are expressed as the means ± SEM from three independent experiments (n = 5 mice per group). ∗p <0.05; ∗∗p <0.01.
Figure 3Trichinella spiralis infection suppresses proinflammatory cytokine production in mice with collagen-induced arthritis (CIA)
(A) Cytokine levels in the serum from mice of control, CIA and T. spiralis (Ts) infected CIA groups were analyzed by Luminex xMAP assay on day 49 after the first immunization with type Ⅱ collagen (CⅡ).
(B) The expression levels of proinflammatory cytokine-related genes in synovial tissues isolated from the hind paws of mice on day 49 were analyzed by RT-qPCR.
(C) M1-related cytokine levels were measured by ELISA in culture supernatants of macrophages collected from the peritoneal cavities of mice from the different groups and stimulated with 100 ng/mL lipopolysaccharide (LPS).Data are expressed as the means ± SEM from three independent experiments (n = 5 mice per group). ∗p <0.05; ∗∗p <0.01; ∗∗∗p <0.001.
Figure 4Trichinella spiralis MES inhibits LPS-induced M1 polarization and enhances IL-4-induced M2 polarization in RAW264.7 macrophages in vitro
RAW264.7 macrophages were pre-incubated with MES (4, 8, or 16 μg/mL) for 2 h prior to the addition of LPS (100 ng/mL) or IL-4 (20 ng/mL) to induce M1 or M2 polarization, respectively. The effect of MES on the expression of M1 phenotype- (A) or M2 phenotype-associated genes (B) was analyzed by RT-qPCR after 6 h of stimulation with LPS or IL-4. M1- (C) and M2-related (D) cytokine levels in the culture supernatants of RAW264.7 macrophages were measured by ELISA. The experiments were repeated three times. The data are expressed as means ±SEM∗p <0.05; ∗∗p <0.01; ∗∗∗p <0.001.
Figure 5The percentage of M1 among blood monocytes positively correlated with the number of RANKL-induced osteoclasts (OCs) in rheumatoid arthritis (RA) patients
(A) M1 monocytes were defined as CD14+, CD68+, and CCR2+.
(B) Blood monocytes from PBMCs of RA patients were stimulated with RANKL (50 ng/mL) and M-CSF (30 ng/mL) for 5 days to induce OCs and then stained with TRAP. Representative TRAP staining (scale bar, 500 μm and 200 μm) of the OCs (red arrows) differentiated from blood monocytes of RA patients with relatively higher or lower percentage of M1 were showed respectively.
(C) Spearman’s correlation analysis for the numbers of OCs and the M1 percentage in blood monocytes of RA patients. The experiments were repeated three times. The data are expressed as means ±SEM.
Figure 6Trichinella spiralis MES suppresses proinflammatory cytokine production in blood monocytes from rheumatoid arthritis (RA) patients
Blood monocytes from RA patients were pre-incubated with MES (8 μg/mL) for 2 h prior to the stimulation with LPS (100 ng/mL). The levels of the cytokines IL-6, TNF-α, IL-1β, and IL-10 in the culture supernatants were measured by ELISA. The experiments were repeated three times. The data are expressed as means ±SEM∗p <0.05, ∗∗p <0.01.
Figure 7Trichinella spiralis MES alleviates bone erosion and inhibits osteoclastogenesis in the joints of mice with collagen-induced arthritis (CIA)
(A) The regimen of study including the induction of CIA and treatment with MES.
(B) Representative 3D images of the hind paws from mice of control, CIA or CIA + MES groups (left panel). The bone volume/total volume ratio (BV/TV) and trabecular thickness (Tb.Th) were quantified in the different groups of mice (right panel).
(C) Joint synovium sections were stained with TRAP (left panel, scale bar, 200 μm) and the numbers of osteoclasts (OCs) per view field were counted using ImageJ software (right panel). The results are expressed as the means ± SEM from three independent experiments (n = 5 mice per group). ∗∗p <0.01.
Figure 8Trichinella spiralis MES suppresses LPS-enhanced and RANKL-induced osteoclast differentiation
RAW264.7 cells were first treated with MES (8 μg/mL) and LPS for 6 h, and then exposed to murine RANKL (50 ng/mL) for 5 days.
(A) Representative TRAP staining (left panel, scale bar, 200 μm and 100 μm) and the numbers of osteoclast (OCs) were counted per field of view (right panel) (OCs are indicated by red arrows).
(B) The mRNA levels of cathepsin k, MMP-9, RANK, and TRAP were detected by RT-qPCR.
(C) Equal amounts of RAW264.7 lysate (40 μg) were separated by 12% SDS–PAGE and then subjected to western blot with antibodies targeting molecules in the NF-κB and MAPK signaling pathways and NFAT. The results are expressed as the means ± SEM from three independent experiments. ∗p <0.05, ∗∗p <0.01.
| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---|---|---|
| Antibodies | ||
| PerCP anti-mouse/human CD11b Antibody | Biolegend | Cat#101229; RRID: |
| Alexa Fluor® 488 anti-mouse CD115 (CSF-1R) Antibody | Biolegend | Cat#135512; |
| CD206 (MMR) Monoclonal Antibody (MR6F3), APC, eBioscience™ | invitrogen | Cat#17-2061-82; |
| F4/80 Monoclonal Antibody (BM8), FITC, eBioscience™ | invitrogen | Cat# 11-4801-82; |
| iNOS Monoclonal Antibody (CXNFT), PE, eBioscience™ | ebioscience | Cat#12-5920-82; |
| PE Rat IgG2a, κ Isotype Ctrl Antibody | Biolegend | Cat#400507; |
| Rat IgG2b kappa Isotype Control (eB149/10H5), APC, eBioscience™ | ebioscience | Cat#17-4031-81; |
| CD14 Monoclonal Antibody (61D3), APC-eFluor 780, eBioscience™ | ebioscience | Cat#47-0149-42; |
| CD68 Monoclonal Antibody (eBioY1/82A (Y1/82A)), PE, eBioscience™ | ebioscience | Cat#12-0689-42; |
| BD Horizon™ BV421 Mouse Anti-Human CD192 (CCR2) | BD | Cat#564067; |
| Anti-F4/80 antibody [CI:A3-1] | Abcom | Cat#ab6640; |
| Anti-Mannose Receptor antibody | Abcom | Cat#ab64693; |
| Anti-iNOS antibody | Abcom | Cat#ab15323; |
| Goat Anti-Rabbit IgG H&L (HRP) | Abcom | Cat#ab6721; |
| Mounting Medium With DAPI - Aqueous, Fluoroshield | Abcom | Cat#ab104139 |
| NF-κB p65 (D14E12) XP® Rabbit mAb | Cell Signaling Technology | Cat#8242; |
| Phospho-NF-κB p65 (Ser536) (93H1) Rabbit mAb | Cell Signaling Technology | Cat#3033; |
| IκBα (44D4) Rabbit mAb | Cell Signaling Technology | Cat#4812; |
| Phospho-IκBα (Ser32) (14D4) Rabbit mAb | Cell Signaling Technology | Cat#2859; |
| Phospho-SAPK/JNK (Thr183/Tyr185) (81E11) Rabbit mAb | Cell Signaling Technology | Cat#4668; |
| p38 MAPK (D13E1) XP® Rabbit mAb | Cell Signaling Technology | Cat#8690; |
| Phospho-p38 MAPK (Thr180/Tyr182) (D3F9) XP® Rabbit mAb | Cell Signaling Technology | Cat#4511; |
| Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (D13.14.4E) XP® Rabbit mAb | Cell Signaling Technology | Cat#4370; |
| p44/42 MAPK (Erk1/2) (L34F12) Mouse mAb | Cell Signaling Technology | Cat#4696; |
| SAPK/JNK Antibody | Cell Signaling Technology | Cat#9252; |
| Phosphoto-SAPK/JNK (Thr183/Tyr185) (81E11) Rabbit mAb | Cell Signaling Technology | Cat#4668; |
| NFAT1 (D43B1) XP® Rabbit mAb | Cell Signaling Technology | Cat#5861; |
| β-Actin (13E5) Rabbit mAb | Cell Signaling Technology | Cat#4970; |
| IRDye 800CW Goat anti-Rabbi | Li-cor | Cat#926–32211 |
| Chemicals, peptides, and recombinant proteins | ||
| Immunization Grade BovineType II Collagen | Chondrex | Cat#20022 |
| Complete Freund's Adjuvant | Chondrex | Cat#7001 |
| Incomplete Freund's Adjuvant | Chondrex | Cat#7002 |
| Mouse 1× Lymphocyte Separation Medium | DAYOU | Cat#7211011 |
| Histopaque®-1083 | Sigma-Aldrich | Cat#10831-100ML |
| Lipopolysaccharide (LPS) Solution (500X) | invitrogen | Cat#00-4976-93 |
| Recombinant Murine IL-4 | PeproTECH | Cat#214-14 |
| Recombinant Murine sRANK Ligand (E.coli derived) | PeproTECH | Cat#315-11 |
| Recombinant Murine M-CSF | PeproTECH | Cat#315-02 |
| Recombinant Human M-CSF | PeproTECH | Cat#300-25 |
| Recombinant Human sRANK Receptor | PeproTECH | Cat#310-08 |
| RIPA | Solarbio | Cat#R0010 |
| Protease inhibitor ,Cocktail ,50x | APPLYGEN | Cat#P1265 |
| IC Fixation Buffer | invitrogen | Cat#00-8222-49 |
| 10×Permeabilization Buffer | invitrogen | Cat#88-17000-210 |
| Critical commercial assays | ||
| Human IL-10 Precoated ELISA Kit | DAYOU | Cat#1111002 |
| Human IL-6 Precoated ELISA Kit | DAYOU | Cat#1110603 |
| Human IL-1 β Precoated ELISA Kit | DAYOU | Cat#1110123 |
| Human TNF-α Precoated ELISA Kit | DAYOU | Cat#1117202 |
| IL-6 Mouse Uncoated ELISA Kit | Invitrogen | Cat#88-7064-88 |
| IL-1 beta Mouse Uncoated ELISA Kit | Invitrogen | Cat#88-7013-88 |
| TNF alpha Mouse Uncoated ELISA Kit | Invitrogen | Cat# 88-7324-77 |
| IL-10 Mouse Uncoated ELISA Kit | Invitrogen | Cat# 88-7105-88 |
| Pierce™ BCA Protein Assay Kit | Thermo Scientific | Cat#23227 |
| ProcartaPlex multiplex protein assays | Thermo Scientific | N/A |
| Opal 7-Color Manual IHC Kit | PerkinElmer | Cat#NEL811001KT |
| Experimental models: Cell lines | ||
| RAW264.7 | BMCR | |
| Experimental models: Organisms/strains | ||
| ICR mice | The Jackson Laboratory | RRID:IMSR_JAX:009122 |
| DBA/1 mice | Mouse Genome Informatics | RRID:MGI:2159837 |
| C57BL/6J | The Jackson Laboratory | RRID:IMSR_JAX:000664 |
| This paper | ISS 533 | |
| RA patients and healthy donors | Beijing Friendship hospital, Capital Medical University | N/A |
| Oligonucleotides | ||
| Primers for RT-qPCR, see | This paper | N/A |
| Software and algorithms | ||
| mimics | Materialise | |
| Image J | National Institutes of Health | |
| Prism 9.0 | GraphPad | |